| intermediate name | technical package | usa secondary dmf | canada secondary dmf |
|---|---|---|---|
| betamethasone base | √ | ||
| desoxycortisone base & acetate | √ | ||
| dexamethasone base | √ | ||
| diflorasone base | √ | ||
| flumethasone base | √ | √ | √ |
| sirolimus | |||
| staurosporine (int of midostaurin) | √ | √ | |
| tetraene acetate(3tr) | √ | ||
| 16 alpha hydroxyl prednisolone （budesonide &ciclesonideint） | √ | √ | √ |
| 16 alpha-methyl epoxide (8-dm) | √ | √ | |
| 16 beta-methyl epoxide (db-11) | √ | √ | |
| 10-dab (10-deacetylbaccatinⅲ) | √ | √ | |
| pax100（565456-77-1）methyl(1r,2s,5s)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylate hydrochloride | √ | ||
| pax160（2628280-48-6）(s)-2-amino-3-((s)-2-oxopyrrolidin-3-yl)propanamidehydrochloride | √ | ||
| px105（62965-35-9）(s)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoicacid | √ |
※ disclaimer:
products protected by valid patents in this list are for laboratory analytical/research purposes only and are not offered for sale in countries or area wherethe sale of such products constitutes a patent infringement.any liability is at buyer's risk.